In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
The 2023 American Society of Hematology (ASH) Annual Meeting and Exposition saw more than 7000 abstracts, with a focus placed on real-world data and practice-changing updates. A major theme of this year's meeting was a timely one: What can clinicians and researchers do to close persistent disparities in care and foster health equity?
An area of great need is multiple myeloma, with outcomes still far worse among Black patients in the United States compared with White patients despite potentially favorable cytogenetic disease characteristics and a plethora of novel treatments that have improved multiple myeloma outcomes overall.
In today's episode, Raymond Thertulien, MD, PhD, director of multiple myeloma and plasma cell disorders at Novant Health, is joined by Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, to discuss ASH 2023 data and the drivers of racial disparities in multiple myeloma outcomes. They spoke on a range of topics, including unacceptable gaps in access to the latest treatments, underuse of diagnostics such as cytogenetic testing, and society-level barriers to equitable care for Black patients with multiple myeloma.
Listen above or through one of these podcast services:
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More